Research progress and clinical challenges of semaglutide in the treatment of obesity and related metabolic diseases
- VernacularTitle:司美格鲁肽治疗肥胖及相关代谢性疾病的研究进展及临床挑战
- Author:
Xinying ZHANG
1
;
Yingying ZHOU
1
;
Xiaodan FU
2
;
Xianfeng ZHANG
2
Author Information
1. Fourth Clinical College，Zhejiang Chinese Medical University，Hangzhou 310051，China
2. Dept. of Endocrinology and Metabolism，Hangzhou First People’s Hospital，Hangzhou 310006，China
- Publication Type:Journal Article
- Keywords:
semaglutide;
glucagon-like peptide-1 receptor agonist;
obesity;
metabolic diseases;
clinical challenges
- From:
China Pharmacy
2025;36(17):2205-2210
- CountryChina
- Language:Chinese
-
Abstract:
As a novel long-acting glucagon-like peptide-1 （GLP-1） receptor agonist， semaglutide plays a pivotal role in the treatment of obesity and related metabolic diseases. This article systematically reviews the research progress of semaglutide in the treatment of obesity and related metabolic diseases from three aspects： mechanism of action， clinical applications， and existing challenges. It is found that its mechanism of action involves multi-organ synergistic regulation and metabolic intervention. Its clinical applications encompass the treatment of obesity， diabetes， polycystic ovary syndrome， and liver-related metabolic syndromes， and it demonstrates groundbreaking value in cardiovascular and renal protection. However， it still faces multiple challenges in terms of adverse reactions， individualized treatment， economic accessibility， ethical controversies， and risks. In the future， it is essential to further accumulate long-term safety data on semaglutide， optimize combination treatment regimens， and address key issues such as individualized medication for special populations， in order to fully realize its clinical application value.
